Navigation Links
Data From Post-Hoc Analyses Presented at EASD Examine Safety Profile of Linagliptin in Adults with Type 2 Diabetes
Date:9/24/2013

ic clinical development and medical affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "These findings provide healthcare providers with additional information they may need to help manage the increasing number of adults with type 2 diabetes they work with every day."

The U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA) and several other regulatory authorities worldwide have approved linagliptin for the treatment of adults with T2D as monotherapy or in combination with metformin, metformin + sulfonylurea, and as add-on therapy to insulin. With linagliptin, no dose adjustment is required regardless of declining renal function or hepatic impairment.3,4

What are TRADJENTA tablets? 
TRADJENTA is a prescription medicine that is used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

TRADJENTA is not for people with type 1 diabetes or for people with diabetic ketoacidosis (increased ketones in the blood or urine).

If you have had inflammation of the pancreas (pancreatitis) in the past, it is not known if you have a higher chance of getting pancreatitis while you take TRADJENTA.

Important Safety Information

What is the most important information I should know about TRADJENTA? 
Serious side effects can happen to people taking TRADJENTA, including inflammation of the pancreas (pancreatitis), which may be severe and lead to death. Before you start taking TRADJENTA, tell your doctor if you have ever had pancreatitis, gallstones, a history of alcoholism, or high triglyceride levels.

Stop taking TRADJENTA and call your doctor right away if you have pain in your stomach area (abdomen) that is severe and will not go away. The pain may be felt going from your abdomen through to your back. The pain may happen with or without vomiting. These may be symptoms of pancreatitis.

Who should not take TRADJENTA? 
Do not take TRADJENTA if you
'/>"/>

SOURCE Eli Lilly and Company; Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. First assessment of individual RLS domains in new post-hoc analyses of Neupro® studies
2. New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinsons disease
3. Early Coronary Artery Healing Advantage of OrbusNeichs Combo Dual Therapy Stent™ Compared to the TAXUS® Stent Shown in Two Clinical Trial Subgroup Analyses
4. Discovery Labs Presents Final Assessment in a Series of Pharmacoeconomic Analyses that Explore Impact of Reintubation on Healthcare Costs
5. Ibrutinib Phase 2 Data: Analyses Show Efficacy with Ibrutinib Monotherapy in Patients with Relapsed or Refractory Mantle Cell or Diffuse Large B-cell Lymphoma
6. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
7. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
8. Worldwide Multicenter Experiences with CardioFocus HeartLight® EAS to be Presented at Heart Rhythm 2012
9. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
10. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
11. eCardios CEO to Speak During "Act at the Speed of Opportunity" Event Presented by Comcast Business Class and Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... --  myMatrixx, a pharmacy and ancillary medical benefit manager for workers, ... has awarded myMatrixx with a "Best Places to Work ... row. Best Places to Work is ... Best Companies Group.  The competition, which involves months of ... insurance industry companies with at least 25 employees in ...
(Date:9/17/2014)... , Sept. 17, 2014  NuView Life ... global licensing and collaboration agreement with Otsuka Pharmaceutical ... NuView,s investigative genomic-based diagnostic biomarker to detect cancers ... includes all other future diagnostic-imaging applications. NuView retains ... therapeutic delivery and in-vitro urine screen applications. ...
(Date:9/17/2014)... Cardiac Dimensions ® , Inc. today announced ... II clinical trial of its enhanced CARILLON Mitral ... mitral regurgitation, functional improvement, quality of life and ... data, which was consistent with previous trials of ... 26 th annual Transcatheter Cardiovascular Therapeutics Conference ...
Breaking Medicine Technology:myMatrixx Honored with "Best Places to Work in Insurance" Award 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3
... , SAN MATEO, Calif., July 24 ... the preliminary results of a short-term clinical study (Study ... following pretreatment with an FDA-approved topical anesthetic. As part ... U.S. Food and Drug Administration (FDA) requested the study ...
... G rowth factor enhances ... stem cells , , BOSTON, July ... Boston have now laid the groundwork for regenerating heart tissue after a heart ... In the July 24 issue of Cell , they show that a ...
Cached Medicine Technology:NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 2NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 3NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study 4Injection Reverses Heart-Attack Damage 2Injection Reverses Heart-Attack Damage 3
(Date:9/17/2014)... (PRWEB) September 17, 2014 Fasoo ... Security Testing (SAST) tool, at AppSec USA 2014 in ... 9 am to 6 pm at booth G4 inside ... of the leading software security conferences for developers, auditors, ... tool that provides developers and managers with the ability ...
(Date:9/17/2014)... world-leading provider of scientific, technical and medical information ... a position statement by the European Menopause and ... on the topic of breast cancer screening. ... in women, with slightly more than ten percent ... is a well-established method to detect breast cancer. ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 In ... Services, Inc.’s Drug Benefit News (DBN) continues to ... reported in its Aug. 8 issue , CVS ... exclusion lists for 2015 each cut more drugs ... much savings these exclusions are likely to achieve. ...
(Date:9/17/2014)... 17, 2014 In a continuing effort ... Nile virus threats, Mosquito Shield of the South Shore ... with the Hanover Youth Athletic Association to treat area ... daily practices going until dusk, prime mosquito feeding time, ... athletes, coaches, and parents involved in outdoor athletic activities. ...
(Date:9/17/2014)... 17, 2014 According to new ... the leading global authority in medical device market ... regeneration market is expected to exceed $3.7 ... breast reconstruction, hernia repair, dural repair, vaginal slings, ... dental soft tissue regeneration. , Approximately 300,000 ...
Breaking Medicine News(10 mins):Health News:Fasoo to Introduce Their Testing Tool to Improve Software Security and Quality at AppSec USA 2014 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 3Health News:Mosquito Shield of South Shore Again Partners with Hanover Youth Athletic Association 2Health News:Bilateral Breast Reconstruction Rate in the U.S. is one of the Highest in the World 2Health News:Bilateral Breast Reconstruction Rate in the U.S. is one of the Highest in the World 3
... March 10 Speaker Nancy Pelosi and Majority Whip James E. Clyburn held a photo opportunity this afternoon with representatives from the National Association of Public ... ... ... ...
... uncovered a mechanism for resistance to paclitaxel in ovarian ... chemotherapy resistance. Mohamed K. Hassan, Ph.D., a ... research as a collaborative study with his colleagues when ... in Egypt. Results of this study were presented at ...
... treating tumors with extreme heat or moderate heat may ... presented at the second AACR Dead Sea International Conference ... the Clinic, held March 7-10, 2010. "Low ... in curing both malignant and benign tumors using minimally ...
... , March 10 Omega Protein Corporation (NYSE: OME ), the nation,s leading producer of Omega-3 fish oil and specialty fish meal ... with net income of $12.6 million ( $0.69 per share) for the year ended December 31, 2008 . , ... ... ...
... 10 International Merchant Advisors, Inc. (PK: IMAI) ... announced today that the company is preparing to ... Organic Science, Inc.  Organic Science, Inc. is intended to become ... and is focused on the implementation of Organic,s  plans for ...
... March 10 As part of its continued focus on developing programs designed to meet employers, needs, Regence has acquired the assets of Kinetix Living Corp., ... ... , ... ...
Cached Medicine News:Health News:Pelosi Remarks at Photo Opportunity with the National Association of Public Hospitals 2Health News:Omega Protein Reports 2009 Results 2Health News:Omega Protein Reports 2009 Results 3Health News:Omega Protein Reports 2009 Results 4Health News:Omega Protein Reports 2009 Results 5Health News:Omega Protein Reports 2009 Results 6Health News:Omega Protein Reports 2009 Results 7Health News:Omega Protein Reports 2009 Results 8Health News:International Merchant Advisors to Complete Purchase of Medical Marijuana Company Organic Science, Inc. 2Health News:International Merchant Advisors to Complete Purchase of Medical Marijuana Company Organic Science, Inc. 3Health News:Regence Invests in Kinetix Living Corp. 2Health News:Regence Invests in Kinetix Living Corp. 3
... The ThromCat™ System is the first thrombectomy ... strength and simplicity for the full range ... Heliflex™ technology, the new ThromCat™ System flushes, ... of 700 mmHg and incorporates advanced vessel-wall ...
... telescoping plate design integrates the ... and vertebral column spacer. This ... need for supplemental fixation while ... bone graft to be delivered ...
... Tendril ST leads are ... leads, designed to bring ... and flexibility to you ... pre-formed "J leads are ...
The MYO-VAD is a novel cardiac support system with unique, life-saving features....
Medicine Products: